Abstracts tagged "immunology"

Abstract Number: 0010 • ACR Convergence 2021
Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19
Matthew Woodruff¹, Richard Ramonell², Ankur Singh Saini², Mark Rudolph³, F. Eun-Hyung Lee² and Iñaki Sanz⁴, ¹Emory University, Decatur, GA, ²Emory University, Atlanta, GA, ³Exagen Inc., Vista, CA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: An emerging feature of COVID-19 is the identification of autoreactivity in patients with severe disease that may contribute to disease pathology, however the origins…
Abstract Number: 0539 • ACR Convergence 2021
Vgll3-transgenic Autoimmune Mice Display Features of Cutaneous Fibrosis
Mehrnaz Gharaee-Kermani¹, Allison Billi², Marisa Hildebrandt², Jacob Martens³, Rachael Wasikowski², Joanne (Michelle) Kahlenberg¹ and Johann Gudjonsson², ¹Internal Medicine - Division of Rheumatology and Department of Dermatology, University of Michigan, Ann Arbor, MI, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI
Background/Purpose: Fibrosis is characterized by collagen deposition, fibro/myofibroblast accumulation, and extracellular matrix remodeling and can lead to disfiguring skin changes. In cutaneous lupus, scar formation…
Abstract Number: 1509 • ACR Convergence 2021
Pharmacological Inhibition of MALT1 Reverses Activation-Induced Metabolic Reprogramming and Ameliorates Autoimmune Pathogenesis in Multiple Animal Models of Chronic Inflammation
Subhabrata Biswas, Mya Steadman, Ynes Helou, Katherine Sellers, Keng Soh, Aditi Chalishazar, Mehmet Badur, Joanna DiSpirito, Brian DeChristopher, John Monroe, Dania Rabah, Barbara Fox and Andy Long, Rheos Medicines, Inc, Cambridge, MA
Background/Purpose: Current therapies for autoimmune and inflammatory diseases generally target select disease nodes, often failing to produce durable clinical remission. Chronic inflammation is associated with…
Abstract Number: 0015 • ACR Convergence 2021
Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules
Shanshan Zhang¹, Hideaki Tsuji¹, Hui Jin², Koji Kitagori¹, Shuji Akizuki³, Kosaku Murakami¹, Ran Nakashima¹, Hajime Yoshifuji¹, Masao Tanaka¹, Hisashi Arase², Koichiro Ohmura⁴ and Akio Morinobu¹, ¹Kyoto University, Kyoto, Japan, ²Osaka University, Osaka, Japan, ³Kyoto Universtiy, Kyoto City, Japan, ⁴Kobe City Medical Center General Hospital, Kobe, Japan
Background/Purpose: Rheumatoid factor (RF) is an autoantibody that binds to IgG Fc region (CH2 and CH3 domains) and is detectable in patients with rheumatoid arthritis…
Abstract Number: 0648 • ACR Convergence 2021
Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative
Beth Rutstein¹, Melissa Argraves², Atiye Bilgic Dagci², Sarah Bayefsky², Julia Rood², Julie Chase³, Jay Mehta², Melissa Lerman², Cory Stingl⁴ and Jon Burnham², ¹Children's Hospital of Philadelphia, Wynnewood, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Durham, NC
Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…
Abstract Number: 1511 • ACR Convergence 2021
Investigation of Antigen Specific CD4+ T Cells in Patients with Idiopathic Inflammatory Myopathies
Begum Horuluoglu¹, Angeles Shunashy Galindo-Feria², Karine Chemin³, Genadiy Kozhukh⁴, Anatoly Dubnovitsky⁴, Vivianne Malmström⁵ and Ingrid E Lundberg⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Division of Rheumatology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) also known as myositis, are rare chronic autoimmune disorders represented by lesions in muscle, skin and lung. One of the…
Abstract Number: 0024 • ACR Convergence 2021
Heterogeneity of Inflammatory HLA-DR+ Synovial Fibroblasts in Rheumatoid Arthritis Is Driven by Responses to Leukocyte-Derived Cytokines
Melanie Smith¹, Alejandro Kochen¹, Vianne Gao², Michail Schizas², Edward DiCarlo¹, Susan Goodman¹, Christina Leslie³, Laura Donlin¹ and Alexander Rudensky⁴, ¹Hospital for Special Surgery, New York, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Computational and Systems Biology Program Memorial Sloan Kettering Cancer Center, New York, NY, ⁴Memorial Sloan Kettering Cancer Center / Howard Hughes Medical Institute, New York, NY
Background/Purpose: Treatment-refractory rheumatoid arthritis (RA) represents a major unmet need with substantial societal burden. Targeting RA-associated fibroblast-like synoviocytes (FLS) may provide a less-immunosuppressive therapeutic option.…
Abstract Number: 0698 • ACR Convergence 2021
Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue
Andrew Zlobin, Peter Pytel and Vladimir Liarski, University of Chicago, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) – dermatomyositis (DM), polymyositis, and inclusion body myositis - are poorly understood autoimmune muscle disorders. Isolation of relevant immune cell…
Abstract Number: 1512 • ACR Convergence 2021
Epigenetic and Transcriptional Programs of CD4+ T Cell Anergy
Philip Titcombe, Milagros Silva Morales and Daniel Mueller, University of Minnesota, Minneapolis, MN
Background/Purpose: T cell tolerance is essential for preventing autoimmune diseases and resolving inflammation. To maintain tolerance, CD4+ T cells recognizing self-antigens in the periphery can…
Abstract Number: 0025 • ACR Convergence 2021
The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis
Kathrine Pedersen¹, Morten Aagaard Nielsen², Malene Hvid¹, Bent Deleuran¹ and Stinne Greisen¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University / Aarhus University Hopital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium. Despite a variety of treatments, 30-40% of RA patients fail…
Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Emilie Stavnsbjerg Larsen¹, Anna Christine Nilsson², Ulrik Stenz Justesen¹, Anne Voss³ and Isik Somuncu Johansen⁴, ¹Odense University Hospital, Odense C, Denmark, ²Odense Universitets Hospital, Odense C, Denmark, ³Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁴Odense University Hospital, Odense, Denmark
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…
Abstract Number: 1528 • ACR Convergence 2021
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
William West¹, Therese Posas-Mendoza², Jerald Zakem³, William Davis¹ and Robert Quinet⁴, ¹Ochsner Medical Center, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, LA, ³Ochsner Health Systems, Metairie, LA, ⁴Ochsner Health, River Ridge, LA
Background/Purpose: Intravenous immunoglobulin (IVIG) is a blood product created by pooling of donor plasma that is used for a wide range of indications. IVIG is…
Abstract Number: 0046 • ACR Convergence 2021
Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts
Hanna Johnsson¹, John Cole¹, Stefan Siebert¹, Iain McInnes² and Gerard Graham¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Up to 30% of patients with psoriasis develop psoriatic arthritis (PsA). The traditional assumption is that the skin disease is the same in both…
Abstract Number: 0961 • ACR Convergence 2021
Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
Caroline Diorio¹, Rawan Shraim¹, Laura Vella¹, Josephine Giles², Amy Baxter², Derek Oldridge², Scott Canna¹, Sarah Henrickson¹, Kevin Mcnerney¹, Frances Balamuth¹, Chakkapong Burudpakdee¹, Jessica Lee¹, Tomas Leng¹, Alvin Farrell¹, Michele Lambert¹, Kathleen Sullivan¹, John Wherry³, David Teachey¹, Hamid Bassiri¹ and Edward Behrens¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³UPenn, Philadelphia, PA
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Children…
Abstract Number: 1546 • ACR Convergence 2021
Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
Ingrid Jyssum¹, Anne Therese Tveter¹, Fridtjof Lund-Johansen², Ludvig Munthe², Sella Provan¹, Kristin Jørgensen³, Gunnveig Grødeland², Grete Kro², David Warren², Joseph Sexton¹, Tore Kvien¹, Siri Mjaaland⁴, Espen Haavardsholm¹, John Torgils Vaage², Silje Watterdal Syversen¹ and Guro Goll¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Oslo University Hospital, Oslo, Norway, ³Akershus University Hospital, Lørenskog, Norway, ⁴Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: To assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive medication for inflammatory arthritis.Methods: Adult patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].